RNA interference (RNAi) technology has gradually become a cutting-edge technology for treating diseases such as genetic ...

Achilles Therapeutics has torn up its strategy. The British biotech is stopping work on its clinical-phase cell therapy, ...

Keith Speights has positions in Pfizer and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Merck, Pfizer, and Vertex Pharmaceuticals. The Motley Fool recommends Moderna. The ...

DNA (pDNA) purification system. PlasmidPro enables innovation at scale, providing complete automation across mini and maxi ...

Jim Cramer’s 10 Best Stock Picks for Investors Right Now. In this article, we are going to take a look at where Moderna, Inc.

Cartesian Therapeutics has a strong cash position after a $130 million equity raise, extending its runway to support upcoming ...

Moderna Inc. (NASDAQ: MRNA) made headlines during the pandemic for its messenger ribonucleic acid (mRNA) technology used in ...

Moderna jolted investors by pushing back its profitability forecast two years, to 2028, and announcing a $1.1 billion cut in R&D spending.

Analyst Thomas Smith of Leerink Partners maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report), retaining the price ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...

Respiratory illnesses like influenza and COVID can change rapidly, requiring the nimble development and delivery of antiviral ...